The gluten-sensitive enteropathy celiac disease is tightly associated with the production of autoantibodies specific for the enzyme transglutaminase 2 (TG2) -activated enzyme conformation. Epitope mapping revealed that they recognize few distinct conformational epitopes that cluster in the N-terminal half of the enzyme. Two of the epitopes were overlapping with the fibronectin binding site in TG2, and none of the epitopes was accessible when TG2 was in a cell surfacebound form. Based on our findings we propose that the autoantibodies are generated against the soluble, catalytically active enzyme, whereas antibodies reactive with cell surfaceassociated TG2 are absent from the response due to negative selection of B cells recognizing membrane-bound self-antigen. The findings give insight into the mechanisms controlling the formation of anti-TG2 autoantibodies in celiac disease.
ABSTRACT
The gluten-sensitive enteropathy celiac disease is tightly associated with the production of autoantibodies specific for the enzyme transglutaminase 2 (TG2) 5 . The mechanisms underlying the activation of autoreactive B cells, however, are not well defined. To gain more insight into this autoimmune response we have characterized the binding of TG2 by a panel of human monoclonal antibodies generated by expression cloning of immunoglobulin genes from single plasma cells of the celiac disease lesion. The antibodies were highly specific to TG2 and bound preferentially to the "open", Ca 2+ -activated enzyme conformation. Epitope mapping revealed that they recognize few distinct conformational epitopes that cluster in the N-terminal half of the enzyme. Two of the epitopes were overlapping with the fibronectin binding site in TG2, and none of the epitopes was accessible when TG2 was in a cell surfacebound form. Based on our findings we propose that the autoantibodies are generated against the soluble, catalytically active enzyme, whereas antibodies reactive with cell surfaceassociated TG2 are absent from the response due to negative selection of B cells recognizing membrane-bound self-antigen. The findings give insight into the mechanisms controlling the formation of anti-TG2 autoantibodies in celiac disease.
INTRODUCTION
Autoantibodies against the enzyme transglutaminase 2 (TG2) are a hallmark of the glutensensitive enteropathy celiac disease (1), a disorder that affects genetically susceptible individuals upon exposure to dietary cereal proteins. The pathogenesis is driven by CD4 + T cells that react with gluten-derived peptides when presented on the disease-associated HLA molecules, HLA-DQ2 and -DQ8 (2) . It is uncertain if the TG2-specific autoantibodies play a pathogenic role in the disease, but the antibodies serve as very accurate diagnostic markers.
Tests measuring anti-TG2 serum antibodies, especially of the IgA isotype, are widely used and have sensitivities and specificities close to 100% (3) . For childhood celiac disease, the recently launched official European diagnostic guidelines are principally based on positive anti-TG2 serology and no longer include biopsy-proven altered gut histology as a mandatory criterion (4) . In addition to being an autoantigen, TG2 plays a role in the generation of gluten T-cell epitopes through conversion of peptide glutamine residues into glutamic acid in a reaction known as deamidation. The TG2-mediated introduction of negative charges in gluten-derived peptides by deamidation raises their binding affinity to the disease-associated HLA molecules, thereby increasing gluten antigenicity (5, 6) . The link between gluten ingestion and production of autoantibodies against TG2 is not well understood, but it has been suggested that TG2-reactive B cells receive help from gluten-reactive CD4 + T cells through receptor-mediated uptake of covalent complexes between TG2 and gluten followed by presentation of gluten-derived peptides on HLA-DQ2 or HLA-DQ8 (7, 8) .
In addition to glutamine deamidation, TG2 catalyzes protein crosslinking through the formation of N  (-glutamyl)lysine isopeptide bonds in a reaction termed transamidation. Both deamidation and transamidation are Ca 2+ -dependent reactions taking place in the extracellular environment (9) . The enzyme is synthesized in the cytosol but is also found in the nucleus as well as outside of cells on the plasma membrane and in the extracellular matrix (ECM).
Intracellularly, TG2 works as a GTPase and presumably acts as a G protein involved in signal transduction (10) . GTP/GDP binds to a pocket on the surface of the protein and inhibits the transamidation/deamidation activity of the enzyme (11, 12) . In the reported crystal structure of TG2 in complex with GDP, the enzyme adopts a "closed" conformation where the Cterminal end is folded in on the core domain and covers the active site (13) . The structure of TG2 with a synthetic peptide inhibitor covalently bound to the active site cysteine has also been solved, revealing an "open", extended conformation where the C-terminal end is displaced 120 Å, and the active site is accessible (14) . The closed conformation presumably represents intracellular TG2, whereas the open conformation is induced extracellularly by the binding of Ca TG2 is exported to the extracellular environment by an unconventional mechanism involving binding to phosphoinositides in endosomal membranes (15) . As a result, the enzyme ends up in a complex with integrins on the cell surface where it has been suggested to act as a fibronectin coreceptor mediating cell adhesion and migration (16) The epitopes recognized by TG2-specific autoantibodies in celiac disease are known to be conformational, thus making it challenging to determine the specific structural regions that are targeted. Recently, however, a single epitope made up of residues from different structural domains was reported as the main epitope in celiac disease based on the loss of serum antibody reactivity toward mutated versions of TG2 (19) . Here we have used a panel of TG2-specific mAbs generated from plasma cells from celiac disease patient small intestinal biopsies to characterize the targeting of TG2 by autoantibodies in detail. We show that almost all of the antibodies bind one of four different epitope regions that seem to be clustered closely together in the N-terminal end of the enzyme. This is hardly coincidental and speaks to a common mechanism regulating the recruitment of TG2-reactive B cells in this autoimmune response.
MATERIALS AND METHODS

Human and animal material
Participating human subjects were diagnosed with celiac disease according to the guidelines of the American Gastroenterology Association. The subjects gave their informed consent before the donation of blood and small intestinal biopsies. Collected serum samples were stored at -20C. Biopsy specimens were cultured in 5% FCS/RPMI-1640 at 37C in the presence of 5% CO2 as previously described (20) . Collected supernatants were stored at -20C. The study was approved by the Regional Ethics Committee of South-Eastern Norway (approval S-97201). C57BL/6 wild-type and TG2 knockout mice (21) were handled according to a locally approved protocol.
Antigens
His-tagged recombinant human TG2 was either expressed in E. coli and purified as previously described (22) or obtained from Phadia as purified protein expressed in Sf9 insect cells.
Mouse TG2 was obtained by extraction of RNA from mouse liver biopsies and cloning of TG2-encoding cDNA into the pET-28a vector (Novagen) as described for human TG2 (23) .
Mouse TG2 and human TG2 mutants were produced in E. coli in the same way as wild-type human TG2. Mutations were introduced in the TG2 sequence using the QuickChange Sitedirected Mutagenesis Kit (Stratagene) and the mutations were confirmed by sequencing (GATC Biotech). The mutants were produced in parallel with the wild-type enzyme. A truncated version of TG2 consisting of aa 1-465 was obtained by PCR amplification of the   TG2  wild-type  construct  using  the  forward  primer  5'-TGCCCATATGGCCGAGGAGCTGGTCTT-3'  and  reverse  primer  5'- GTCAAAGCTTTTACAGTTTGTTCAGGTGGTTCG-3' followed by subcloning into the pET-28a vector between the NdeI and HindIII sites. The human transglutaminases TG3 and TG6 were obtained from Zedira and the Jo-1 autoantigen was from Phadia.
Antibodies
Human mAbs were produced as previously reported (20, 24) . In brief, IgG1 and Ig expression vectors containing the cloned antibody heavy and light chain variable regions, respectively, were co-transfected into HEK293 cells. The antibodies were subsequently purified from cell supernatants on Protein A or Protein G sepharose (GE Healthcare). The mouse mAbs CUB7402 and TG100 were obtained from NeoMarkers and the 4G3 mAb was from Millipore.
ELISA assays
Binding of mAbs to the various antigens was assessed essentially as previously described for TG2 (20) . In general, microtiter plates were coated over night at 4C and blocked by washing the plates with 0.1% Tween20, which was also included in all following incubations with antibodies. Alkaline phosphatase-conjugated rabbit anti-human IgG or rabbit anti-mouse IgG (Abcam) was used to detect binding of mAbs. Goat anti-human IgA (Sigma) was used to detect polyclonal IgA. After addition of phosphatase substrate, absorbance was measured at 405 nm in a microplate reader (Thermo). Saturation binding curves were produced by nonlinear regression analysis of measured OD values at the indicated antibody concentrations. In the cases where only a single or two mAb concentrations were used, these were picked so that sub-saturating levels of mAb were achieved. In one set of experiments, TG2 was preincubated with 5 mM iodoacetamide for 30 min prior to coating of microtiter plates with 5 µg/ml of protein . To investigate the effects of Ca   2+ and GTP, 0.1 mg/ml TG2 was preincubated with 1 mM GTP or 5 mM CaCl2 in TBS for 1 hour at room temperature prior to coating. The TG2 inhibitor KCC009 (25) was included at a concentration of 1 mM in samples with CaCl2 to avoid auto-crosslinking. During coating and incubations with antibodies, the GTP concentration was kept at 50 µM and the CaCl2 concentration was kept at 5 mM.
Antibody incubations were done in TBST. In experiments where TG2 was captured on the 45 kDa gelatin-binding fragment of fibronectin (Sigma), microtiter plates were coated with 2 µg/ml of the fibronectin fragment, followed by addition of 1 µg/ml TG2 produced in Sf9 insect cells. The signals were compared to the ones obtained when plates were coated directly with 3 µg/ml of TG2. In experiments where whole human fibronectin (Sigma) was used to capture TG2, microtiter plates were coated with 10 µg/ml of fibronectin followed by addition of 10 µg/ml TG2 in the presence or absence of 5 mM CaCl2 in TBST. Crosslinking was then allowed to occur for 1 hour at 37C before incubation with antibodies in the absence of Ca
2+
.
Competition ELISA
Small aliquots of purified mAbs were biotinylated with the EZ-link sulfo-NHS-LC-biotin reagent (Pierce) following the standard protocol. Binding of biotinylated mAbs to TG2 was assessed as described above except that alkaline phosphatase-conjugated streptavidin (Southern Biotech) was used to detect bound mAbs. For each biotinylated mAb, a concentration falling in the dynamic range of the ELISA assay was chosen and used in the subsequent competition experiments. These were performed in the following way: 5-10 µg/ml of unlabeled competitor mAb was added to TG2-coated microtiter plates. After 30 min incubation at 37C, one tenth of the volume was removed and replaced with an equal volume of biotinylated mAb giving the optimal, predetermined concentration of labeled mAb. The resulting competitor mAb / biotinylated mAb ratio was between 10 and 50 in all experiments.
After addition of labeled mAb, incubation was continued for 1 hour at 37C and the amount of TG2-bound biotinylated mAb was determined as described above. Competition between IgG mAbs and polyclonal IgA was performed in a similar way. After pre-incubation with a mixture of mAbs, each in a concentration of 2 µg/ml, serum or biopsy supernatant was added to the TG2-coated microtiter plate. Bound IgA was subsequently detected as described above.
Non-denaturing PAGE
The conformational states of TG2 were analyzed by non-denaturing PAGE as previously reported (22) . TG2 was either loaded directly or pre-incubated with different reagents prior to mixing with loading buffer and commencement of electrophoresis. Incubations were carried out at room temperature for 30 min in TBS including either 5 mM iodoacetamide, 1 mM GTP or 5 mM CaCl2 in combination with 1 mM KCC009 inhibitor.
Immunofluorescence
Mouse small intestine was embedded in optimal cutting temperature (OCT) medium (TissueTek) and snap frozen in liquid nitrogen. Dried, unfixed 6 µm cryosections were stained with 6 or 3 µg/ml of each of the indicated mAbs in 1.25% BSA/PBS at room temperature for 1 hour followed by FITC-conjugated goat anti-human IgG (Southern Biotech). Nuclei were stained with Hoechst and the slides were mounted with home-made polyvinyl alcohol. Images were acquired on an inverted fluorescence microscope (Nikon Eclipse Ti-S) with a Nikon 10x/0.3
Plan Fluor lens using the NIS-elements BR3.2 software. TG2 knockout tissue sections were incubated with or without 50 µg/ml recombinant human or mouse TG2 produced in E. coli for 1 hour at room temperature before detection with antibodies as described above. In one set of experiments the TG2 concentration was decreased to 10 µg/ml during incubation with tissue sections. This did not have an effect on the staining results.
Culturing of dendritic cells from monocytes
iDCs were generated from peripheral blood mononuclear cells of healthy blood donors essentially as previously described (26 cells per well and cultured in 1 ml 10% FCS/RPMI-1640 supplemented with 1000 U/ml GM-CSF and 500 U/ml IL-4. On day 2 and 5, half of the culture medium was replaced with fresh medium. The cells were used for analysis on day 7 or 8.
Flow cytometry
iDCs were incubated with 10 µg/ml of each of the indicated mAbs or 100 µg/ml of IgA purified from serum on goat anti-human IgA-agarose (Sigma) for 30 min on ice in 2% 
RESULTS
Most anti-TG2 autoantibodies bind one of four distinct epitopes that correlate with antibody VH gene segment usage
Recently, we reported the cloning of antibody variable regions of single TG2-reactive plasma cells isolated from small intestinal biopsies from four adult individuals with active celiac disease (20) . By expressing the antibodies recombinantly in a human IgG1 format we obtained a panel of anti-TG2 mAbs. The antibodies generally had few somatic mutations and showed bias toward usage of the VH5-51 gene segment. Interestingly, the VH5-51 mAbs had fewer mutations and bound TG2 with lower affinity than mAbs using other VH segments.
Another surprising feature was that none of 47 tested mAbs had an inhibitory effect on TG2 enzymatic activity. We wished to understand more about this autoimmune response and find out if the TG2-reactive autoantibodies share other characteristics. We therefore carried out competitive binding studies to investigate if the antibodies target common epitopes. Initially, 18 mAbs representing each patient were selected randomly, and their ability to compete with each other was analyzed. Several mAbs were found to compete for TG2 binding, but we were able to pick four that showed different competition patterns and therefore most likely recognize different epitopes. Based on the ability of the rest of the mAbs to compete with these four, we divided the entire panel into five distinct groups (Fig. 1A) . The largest group, which was assigned to epitope 1, consists of antibodies competing with mAb 763-4-C06 but not with mAb 763-4-B06. Notably, this group contains almost all of the VH5-51 antibodies in the panel (Fig. 1B) . Likewise, the group with the opposite reaction pattern, assigned to epitope 2, is made up entirely of antibodies belonging to the VH3 family. Thus, the targeted epitopes largely reflect the VH gene segment usage of the antibodies. Epitope 1 antibodies were represented in all four donors, from whom mAbs were generated, whereas the epitope 2 antibodies came from just two of the donors. Antibodies assigned to epitope 3 and 4 competed with both 763-4-C06 and 763-4-B06, suggesting that these epitopes are overlapping with epitope 1 and 2. However, these antibodies could be distinguished based on their ability to compete with two other mAbs, 693-1-A02 and 693-1-B03. Only eight out of 57 mAbs did not compete with any of the labeled antibodies and thus react with one or more different epitopes.
To further characterize the epitopes, the reactivity of the mAbs with mouse TG2
(sharing 84% sequence identity with human TG2) was assessed (Fig. 1B) . Most of the antibodies in the epitope 1 group and both epitope 4 antibodies were reactive with mouse TG2, whereas most of the antibodies binding epitope 3 did not react with mouse TG2. The epitope 2 antibodies showed varying reactivity, suggesting that the antibodies in each group do not necessarily bind TG2 in the same way. The assigned epitopes represent targeted regions rather than exact binding motifs and differences in binding mode can exist within each group.
TG2-reactive autoantibodies are specific and do not cross-react with other transglutaminases
Immunofluorescence staining of small intestinal tissue sections from wild-type or TG2 knockout mice with mAbs reactive or non-reactive with mouse TG2 was found to correspond closely to the expected patterns ( Fig. 2A) . Notably, complete loss of reactivity to TG2-free tissue suggests that the TG2-reactive autoantibodies in our panel are highly specific. Antibody reactivity with TG2 knockout tissue could, however, be established by the addition of recombinant TG2 to the sections, indicating that antibody-targeted TG2 in the tissue is bound to the ECM via specific interactions (Fig. 2B ). To further explore the specificity of the mAbs, we tested their reactivity with other members of the transglutaminase family (Fig. 2C ).
Whereas TG2 is ubiquitously expressed, TG3 and TG6 are found in the skin and brain, respectively. These transglutaminases have also been implicated in autoimmunity as anti-TG3 autoantibodies are associated with dermatitis herpetiformis (ref. 22 , Fig. 2D ) and TG6
autoantibodies have been found in gluten ataxia (28) . Both conditions are associated with gluten sensitivity and anti-TG3 and anti-TG6 autoantibodies were also described in celiac disease. When testing our antibody panel for binding to TG3 and TG6 we found little, if any, reactivity indicating that the antibodies generated against TG2 are not cross-reactive with TG3 and TG6. Moreover, all reactivity was lost when antibody incubations were done in 2% dry milk, indicating that the low degree of binding we saw for some mAbs is due to slight polyreactivity. The same picture was seen for the nuclear autoantigen Jo-1 which is a target for autoantibodies in myositis (29) and was used here as an irrelevant control antigen.
Autoantibodies target an open rather than a closed TG2 conformation
We observed that the reactivity of several antibodies in our panel was dependent on the source The same effects were seen for TG2 produced in E. coli and Sf9 cells (Fig. 3B, 3C) . Notably, the two TG2 preparations became equally potent antigens in the presence of Ca 2+ (Fig. 3D ).
To rule out the possibility that the reaction pattern we observed in ELISA was due to 
Epitopes can be located according to introduced mutations and competition with fibronectin for TG2 binding
To see if any of the epitopes we have assigned to our panel of mAbs coincide with the recently discovered epitope targeted by celiac disease serum autoantibodies (19), we constructed the reported R19S E153S M659S TG2 triple mutant and tested it for binding to mAbs from each epitope group. Introduction of the mutations caused loss of all or most reactivity for the antibodies assigned to epitope 2 and also affected some of the antibodies binding to the overlapping epitope 3 region (Fig. 4A, 4D ). The rest of the antibodies, on the other hand, had comparable reactivity to the mutant and wild-type enzymes, suggesting that the mutations do not interfere with the overall conformation of TG2 but selectively target the epitope 2/3 region.
It has also been suggested that TG2-specific antibodies in celiac disease target the enzyme's active site based on observed loss of reactivity of serum IgA upon replacement of the catalytic triad residues Cys277, His335 and Asp358 with alanine (31) . In contrast to the reported effect on serum antibodies, introduction of these mutations in TG2 did not affect the reactivity of mAbs assigned to the different epitopes to a large degree (Fig. 4A) . Importantly, the two generated triple mutants were both produced with lower yields than the wild-type enzyme and also appeared less pure by SDS-PAGE analysis (Fig. 4B) . Thus, lower quality of the mutant proteins could explain why they in some cases can appear less reactive than the wild-type in ELISA. Unless protein quality is taken into consideration, it can lead to a "false" effect of the mutations being recorded. Accordingly, it can be difficult to distinguish between effects of mutations on the overall protein quality and specific effects on targeted epitopes, especially when one is analyzing polyclonal antibody responses.
The specific binding between TG2 and fibronectin in the ECM involves the gelatinbinding domain of fibronectin (32) and the N-terminal -sandwich domain of TG2 (33) . More specifically, in TG2, aa 88-106, which make up a -hairpin motif, have been implicated in fibronectin binding (34) . To see if the association with fibronectin influences the binding between TG2 and antibody, we tested the ability of mAbs from each assigned epitope group to react with fibronectin-bound TG2. mAbs targeting epitope 1 and 4 were found to lose reactivity when TG2 was associated with fibronectin, suggesting that these epitopes overlap with the fibronectin binding site in TG2 (Fig. 4C, 4D ). This finding was somewhat surprising,
given that all the tested mAbs have been scored as positive in an EMA (EndoMysium Antibody) staining assay where the reactivity of antibodies to natural TG2 in situ is tested (20) . TG2 co-localizes with fibronectin in the ECM and is therefore expected to exist predominantly in a fibronectin-bound state in tissue (35, 36) . It is possible, though, that some TG2 associates with fibronectin through crosslinking rather than the specific non-covalent interaction. In this regard, TG2 has been described to target specific glutamines in fibronectin and is also able to crosslink itself (37) . Interestingly, when TG2 was added to coated fibronectin in the presence of Ca 2+ to allow crosslinking, the resulting complexes were recognized by mAbs that otherwise did not react with fibronectin-bound TG2 in ELISA (Supplemental Fig. 2A 
The reactivity of polyclonal IgA antibodies partly reflects the epitope distribution among
TG2-specific mAbs
In agreement with the findings recently reported by Korponay-Szabo and coworkers (19) we saw that introduction of the R19S E153S M659S triple mutation in TG2 reduces the reactivity of serum IgA as well as IgA secreted by small intestinal biopsies obtained from celiac disease patients (Fig. 5A) . Importantly, however, remaining reactivity could be detected in all cases, indicating that more epitopes are targeted in polyclonal anti-TG2 responses. Mutation of the catalytic triad residues in TG2 did not lead to reduced binding of polyclonal IgA from celiac disease patients (Fig. 5A) , thus supporting our findings with TG2-specific mAbs and strongly suggesting that the TG2 active site is not targeted by autoantibodies in celiac disease.
Association of TG2 with fibronectin was found to give equal or better binding of polyclonal
IgA when comparing the reactivity against TG2 on coated fibronectin to that against directly coated TG2 in ELISA (Fig. 5B) . This was somewhat unexpected, as our results with TG2-specific mAbs indicate that around half of the antibodies target an epitope that overlaps with the fibronectin binding site. However, the association with fibronectin might increase binding of antibodies targeting other epitopes as seems to be the case for the mAb 679-14-D04, for instance (Fig. 4C ). This could be due to increased accessibility of some epitopes, maybe as a result of partial shielding and/or loss of structure induced by direct coating of TG2 to plastic.
It could also be that the association with fibronectin leads to structural changes that increase the binding affinity for some antibodies. Alternatively, additional epitopes may exist in some patients.
Antibodies do not target cell surface-associated TG2
TG2 has been found on the surface of various cell types where it presumably interacts with fibronectin and integrins of the 1 and 3 subfamilies or heparan sulfate proteoglycans (35, 38, 39) . It has also been shown that TG2 can be detected on the surface of dendritic cells and macrophages with the mouse mAb TG100 (40) . To see if our TG2-specific human mAbs
recognize cell surface TG2 we tested the ability of antibodies from each epitope group to stain immature dendritic cells (iDCs) in flow cytometry. None of the tested antibodies stained TG2
on the cells, suggesting that the assigned epitopes are hidden when TG2 is surface-bound (Fig. 6A ). In agreement with this, IgA antibodies purified from serum from a celiac disease patient did not stain cell surface TG2 either. As expected, surface-bound TG2 could be detected with TG100, whereas two other mouse mAbs, CUB7402 and 4G3, gave weak and no staining, respectively.
Since the majority of TG2 is found in the cytosol, we also tested if the mAbs bind TG2
inside iDCs. The three tested human mAbs and TG100 all stained intracellular TG2 after permeabilization (Fig. 6B ). This shows that TG2 inside cells can be recognized by autoantibodies and, thus, exists in a state that differs from the one found on cell surfaces. shows that some of these epitope regions are partly overlapping and suggests that all four are clustered closely together (Fig. 1A) .
DISCUSSION
The mAbs were highly specific to TG2 and did not cross-react with TG3 and TG6 (Fig.   2C ). This indicates that celiac disease autoantibodies against other transglutaminases are generated in an independent immune response and are not a result of cross-reactivity of anti-TG2 autoantibodies. The results are in agreement with previously reported findings with polyclonal serum IgA showing that TG2 and TG6 are targeted by discrete antibody populations (28) . While being specific to TG2, the mAbs were found to discriminate between different sources of recombinant enzyme, as TG2 produced in E. coli gave poorer signals in ELISA than TG2 produced in Sf9 insect cells for a number of mAbs. This could indicate that producing the enzyme in a eukaryotic cell line results in more optimal folding and a conformation which is recognized better by TG2-specific antibodies compared to the standard recombinant expression system using E. coli. The importance of protein folding is in line with our own and others' previous findings stating that the targeted epitopes are conformational (20, 42, 43 and low GDP/GTP concentrations in the extracellular environment.
The recently described TG2 epitope made up of Arg19, Glu153 and Met659 (19) was found to be targeted by the antibodies we have assigned to epitope 2 as well as some epitope 3
antibodies (Fig. 4A, 4D ). The data presented here is in agreement with the previous report saying that this is a main epitope targeted by autoantibodies in celiac disease, but our results indicate that it is not the single most important epitope at the cellular level as it is targeted by relatively few mAbs. Furthermore, for Met659 to be part of an epitope together with Arg19 and Glu153, it is required that TG2 takes a closed conformation, and since the antibodies
preferentially target an open TG2 conformation, all three residues are not likely to be part of the same epitope.
The mAbs we have assigned to epitope 1 and 4 as well as three mAbs not assigned to any of the epitopes were found to compete with fibronectin for binding to TG2 (Fig. 4C, 4D ).
Although we cannot rule out that the observed effect is due to conformational changes in TG2
induced by fibronectin binding, it suggests that the epitopes overlap with the fibronectin binding site. In addition, the results suggest a possible pathogenic role for TG2-reactive antibodies in celiac disease as competition with fibronectin could lead to antibody-induced displacement of TG2 from the fibronectin meshwork in the ECM. The resulting release of immobilized TG2 could possibly lead to increased enzymatic activity as the enzyme is brought into solution. This might explain previously reported findings of increased TG2 activity upon addition of celiac disease antibodies to endothelial cell cultures and the suggested role of the TG2-specific antibodies in increasing endothelial permeability (45) .
Increased enzymatic activity in the celiac lesion could also lead to more gluten deamidation, thereby enhancing the pathogenic T-cell response against deamidated gluten peptides.
The fibronectin binding site in the N-terminal domain is located close to Arg19 and Glu153 in the three-dimensional structure of open TG2 (Fig. 7) . As these two regions represent epitope 1/4 and 2/3, respectively, their location supports our assumption that the assigned epitopes are clustered closely together. In addition, we found that all mAbs, including the ones not assigned to an epitope, were reactive with a truncated version of TG2
lacking the two C-terminal domains (aa 466-687), thus confirming that none of the antibodies targets C-terminal epitopes (not shown). A possible explanation for why the epitopes seem to cluster in the N-terminal end of TG2 is that B cells recognizing epitopes in other parts of TG2 are negatively selected during development. To further explore this possibility we tested if the mAbs are reactive with cell surface-associated TG2 since surface-bound self antigens have been shown to induce deletion or anergy in cognate B cell populations in mice (17, 18). None of the tested mAbs was reactive with TG2 on dendritic cells in contrast to the mouse mAb TG100, which targets a C-terminal epitope in the region made up by aa 447-538 (Fig. 6A ).
This suggests that the assigned, N-terminal epitopes are not accessible when TG2 is found on cell surfaces, possibly due to the association of TG2 with integrins and fibronectin or other interaction partners. The mouse mAb 4G3, which is generated against the N-terminal - . This is in apparent contrast to our data, which suggest that epitope 1 is in the Nterminal domain based on competition of VH5-51 mAbs with fibronectin. It is possible, though, that epitope 1, similarly to epitope 2, includes residues in the core domain together with residues of the N-terminal domain. It has also been suggested that serum IgA targets the active site of TG2 since mutation of the catalytic triad residues Cys277, His335 and Asp358 resulted in loss of antibody reactivity (31) . This is in contrast to our results with both mAbs and polyclonal IgA, showing that antibody binding is not markedly affected by the mutations (Fig. 4A, 5A ). As human antibodies are sensitive to conformational changes in TG2, one reason for this discrepancy could be the use of different recombinant proteins that are not conformationally equal and may behave differently upon introduction of mutations. Hence, in the present study we have used His-tagged protein whereas a GST-TG2 fusion protein was used in the previous study. Our conclusion that the antibodies do not target the active site of TG2 agrees with them not having an inhibitory effect on the activity of the enzyme. It therefore supports our previously suggested model in which the enzymatic activity of BCRbound TG2 is involved in B-cell uptake of TG2-gluten complexes followed by processing and presentation of gluten-derived peptides to CD4 + T cells (20) .
In both our mAb panel (20) and an earlier reported panel of TG2-reactive antibody fragments isolated from phage display libraries (48), the anti-TG2 response was dominated by antibodies using the VH5-51 gene segment. We have shown here that most of the VH5-51
antibodies recognize the same epitope and that this epitope overlaps with the binding site for fibronectin. But despite the overrepresentation of VH5-51 at the single-cell level, polyclonal
IgA did not display decreased binding to fibronectin-associated TG2 (Fig. 5B ). These seemingly contradicting results might be explained by increased binding of antibodies recognizing other epitopes when TG2 is complexed with fibronectin. In addition, we have earlier shown that the VH5-51 mAbs bind TG2 with lower affinity than mAbs using other VH gene segments (20) . Hence, in a polyclonal response, the contribution of VH5-51 antibodies to the overall binding strength will not be proportional to their number. This could also explain the surprisingly large effect of the R19S E153S M659S triple mutation on TG2 reactivity with polyclonal IgA even though the mutation does not disrupt the epitopes recognized by the majority of the mAbs, in particular those using the VH5-51 gene segment.
In summary, by analyzing a panel of 57 TG2-specific mAbs from four adult patients with celiac disease we have found that at least four autoantigenic epitopes in TG2 are clustered in the N-terminal half of the enzyme. We propose that this clustering of epitopes can be explained by a model in which B cells recognizing this region escape from negative selection because the epitopes are not accessible on cell surface-associated TG2. In general, it is likely that B cells reactive with soluble self-antigens can escape negative selection, whereas B cells reactive with cell-surface antigens are deleted or rendered anergic during B cell development. Thus, our findings provide insight into the mechanisms that govern tolerance and autoimmunity by focusing on the targeted epitopes in an ongoing human autoimmune response.
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